Bromfenac Ophthalmic Solution 0.07% (Prolensa) Dosed Once Daily for Cataract Surgery: Results of 2 Randomized Controlled Trials – Corrected Proof
Purpose: To evaluate the efficacy and ocular safety of bromfenac ophthalmic solution 0.07% dosed once daily for the treatment of ocular inflammation and pain in subjects who underwent cataract surgery with posterior chamber intraocular lens implantation.Design: Two phase 3, randomized, double-masked, placebo-controlled, multicenter clinical trials.Participants: Four hundred forty subjects (440 study eyes: 222 in the bromfenac group and 218 in the placebo group).Methods: Two phase 3, prospective, randomized, double-masked, placebo-controlled clinical trials were conducted at 39 ophthalmology clinics in the United States. Subjects 18 years of age or older were randomized to receive either bromfenac 0.07% or placebo dosed once (Read more...)